Illumina (NASDAQ:ILMN) Raised to Outperform at Daiwa Securities Group

Posted by Brenda Bartman on May 16th, 2026

Illumina (NASDAQ:ILMN – Get Free Report) was upgraded by research analysts at Daiwa Securities Group from a “neutral” rating to an “outperform” rating in a note issued to investors on Thursday, Marketbeat reports. The firm presently has a $155.00 price target on the life sciences company’s stock. Daiwa Securities Group’s price objective points to a potential upside of 8.74% from the company’s previous close.

ILMN has been the subject of several other reports. Canaccord Genuity Group cut their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Evercore reissued an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. JPMorgan Chase & Co. increased their target price on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, Robert W. Baird set a $137.00 target price on shares of Illumina in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $137.75.

Read Our Latest Report on Illumina

Illumina Trading Down 0.5%

Shares of NASDAQ:ILMN opened at $142.54 on Thursday. The company has a 50 day moving average of $128.58 and a 200-day moving average of $129.52. The firm has a market cap of $21.57 billion, a P/E ratio of 25.92, a P/E/G ratio of 2.37 and a beta of 1.42. Illumina has a twelve month low of $78.55 and a twelve month high of $155.53. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts anticipate that Illumina will post 5.2 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith A. Meister sold 104,393 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the sale, the director owned 3,500,048 shares in the company, valued at $508,696,976.32. This represents a 2.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 332,530 shares of company stock worth $48,303,655 over the last 90 days. 2.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Illumina

A number of large investors have recently made changes to their positions in ILMN. Empowered Funds LLC raised its holdings in shares of Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after acquiring an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Illumina during the second quarter valued at approximately $621,000. CW Advisors LLC acquired a new stake in shares of Illumina during the second quarter valued at approximately $275,000. Marshall Wace LLP raised its holdings in shares of Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC raised its holdings in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.